Ware Discusses with Reuters the Future of Non-Disclosure Agreements in Sexual Harassment and Misconduct Cases
December 19, 2017
Reuters
Of Counsel Dabney Ware told Reuters in the article “Sexual Misconduct Outcry Makes U.S. Lawyers Rethink Confidentiality” that non-disclosure agreements will likely be on the wane in workplace sexual harassment settlements and that future confidentiality agreements might cover only the names of the parties and the amount paid in the settlement, while allowing allegations to be made public.
Ware said she expects non-disclosure agreements to continue to be used in less egregious cases, or when investigations into harassment claims are inconclusive. “We’re still going to have places where it seems appropriate to keep things confidential, but it’s going to be a lot more limited,” she said.
Ware said she expects non-disclosure agreements to continue to be used in less egregious cases, or when investigations into harassment claims are inconclusive. “We’re still going to have places where it seems appropriate to keep things confidential, but it’s going to be a lot more limited,” she said.
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.